Beauty Farm issues positive profit alert: 1H 2026 revenue projected at ≥RMB1.88 billion, net profit up at least 37%

Bulletin Express
07/20

Beauty Farm Medical and Health Industry Inc. (Beauty Farm) announced a positive profit alert for the six months ended 30 June 2026, indicating substantial top-line and bottom-line growth driven by its “internal growth + external acquisitions” strategy.

Revenue and Earnings • Revenue is expected to exceed RMB1.88 billion, representing growth of no less than 28% year-on-year. • Net profit is projected at a minimum of RMB235 million, up at least 37% from the prior-year period. • Adjusted net profit—excluding share-based compensation, amortisation of acquisition-related intangibles and one-off costs—is anticipated to reach at least RMB260 million, an increase of no less than 36% year-on-year.

Operational Drivers 1. External acquisitions: – The January 2026 consolidation of Siyanli, China’s third-ranked beauty service brand, expanded Beauty Farm’s footprint across premium locations in 20 core cities. – Synergy realisation from both the 2024 acquisition of Naturade and the newly integrated Siyanli contributed to incremental revenue and profitability during the Reporting Period.

2. Internal growth and efficiency: – Same-store sales continued to rise at directly operated outlets, supported by brand upgrades and refined digital operations. – In consumer healthcare, the CellCare aesthetic medical brand introduced expert-driven anti-aging solutions, bolstering service volume and average transaction values. – Ongoing platform efficiencies and economies of scale improved organic profit margins.

Capital-Market Actions Regular share repurchases and a maintained high-dividend policy were highlighted as measures to enhance per-share earnings and reinforce the company’s valuation appeal.

Outlook Management reiterated confidence in achieving full-year growth targets, asserting that the dual-engine strategy and “dual beauty + dual wellness” model will continue to underpin performance momentum.

The interim results for 1H 2026 are still being finalised; figures cited above are based on the Board’s preliminary assessment of unaudited management accounts. Final numbers are scheduled for release by end-August 2026.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10